CA2910652C - Tafa4 compounds and uses thereof for treating pain - Google Patents

Tafa4 compounds and uses thereof for treating pain Download PDF

Info

Publication number
CA2910652C
CA2910652C CA2910652A CA2910652A CA2910652C CA 2910652 C CA2910652 C CA 2910652C CA 2910652 A CA2910652 A CA 2910652A CA 2910652 A CA2910652 A CA 2910652A CA 2910652 C CA2910652 C CA 2910652C
Authority
CA
Canada
Prior art keywords
pain
tafa4
protein
use according
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2910652A
Other languages
English (en)
French (fr)
Other versions
CA2910652A1 (en
Inventor
Aziz Moqrich
Marie-Claire Delfini
Annabelle Mantilleri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Centre National de la Recherche Scientifique
Original Assignee
Aix-Marseille Université
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix-Marseille Université, Centre National de la Recherche Scientifique filed Critical Aix-Marseille Université
Priority to CA3235916A priority Critical patent/CA3235916A1/en
Publication of CA2910652A1 publication Critical patent/CA2910652A1/en
Application granted granted Critical
Publication of CA2910652C publication Critical patent/CA2910652C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2910652A 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain Active CA2910652C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3235916A CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305592.1 2013-05-06
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3235916A Division CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (2)

Publication Number Publication Date
CA2910652A1 CA2910652A1 (en) 2014-11-13
CA2910652C true CA2910652C (en) 2024-05-28

Family

ID=48428409

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2910652A Active CA2910652C (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain
CA3235916A Pending CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3235916A Pending CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107430121B (zh) * 2015-03-13 2020-06-23 希森美康株式会社 受试物质的检测方法及在该方法中使用的试剂盒
CN111683592B (zh) * 2017-10-30 2023-11-03 加利福尼亚大学董事会 使用电化学传感器对分析物进行无校正的体内测量
KR102866162B1 (ko) * 2018-04-24 2025-10-01 주식회사 뉴라클사이언스 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
ES2943136T3 (es) * 2018-09-27 2023-06-09 Inst Nat Sante Rech Med Polipéptido de TAFA4 para su uso para reducir la inflamación cutánea
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease
JP7729824B2 (ja) * 2020-02-13 2025-08-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルガリン酸はｐｉｅｚｏ２媒介性疼痛を低減させる
TWI759788B (zh) * 2020-07-08 2022-04-01 台灣粒線體應用技術股份有限公司 萃取保護液用於自細胞分離粒線體並維持粒線體活性的用途
CA3239578A1 (en) 2021-12-17 2023-06-22 Stephane GAILLARD Peptides and methods for use in treating pain
MX2024007794A (es) * 2021-12-20 2024-07-02 Amgen Inc Peptidos de union a dll3 y usos de los mismos.
EP4499163A1 (en) * 2022-03-24 2025-02-05 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
AU2023278710A1 (en) * 2022-05-31 2024-12-12 Elisigen Inc. Composition for treating retinal or macular diseases
CN120813839A (zh) 2023-02-17 2025-10-17 Naos生命科学研究所 一种用于筛选能够提高皮肤耐受阈值的生态生物型化合物的方法
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
JP2016519138A (ja) 2016-06-30
US9884088B2 (en) 2018-02-06
EP2994157A1 (en) 2016-03-16
EP2994157B1 (en) 2020-07-01
US20160113996A1 (en) 2016-04-28
CA2910652A1 (en) 2014-11-13
JP6487419B2 (ja) 2019-03-20
DK2994157T3 (da) 2020-08-24
CA3235916A1 (en) 2014-11-13
US20180110829A1 (en) 2018-04-26
EP2801369A1 (en) 2014-11-12
ES2813629T3 (es) 2021-03-24
CN105209056A (zh) 2015-12-30
WO2014180853A1 (en) 2014-11-13
CN105209056B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
EP2994157B1 (en) Tafa4 compounds and uses thereof for treating pain
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
WO2018205927A1 (zh) 钾离子通道抑制剂治疗抑郁症的用途和药物组合物
US8252748B2 (en) Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
JP2007530069A6 (ja) イオンチャネル
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
Kamalova Functional characterization of an AMPA receptor auxiliary subunit GSG1L in vivo
Rees Characterization of the 15q13. 3 Microdeletion and Its Effects on Neuronal Excitability, Astrocyte α7 Nicotinic Acetylcholine Receptor Dynamics, and Neuroinflammation
US20240209038A1 (en) Targeting piezo1 to treat inherited and age-related macular degenerations
Dong et al. Low-level expression of Cmyc in mature neurons: Maintaining neuronal function and preventing neurodegeneration
US11878012B2 (en) Compositions and methods for treating traumatic brain injury
Lin Cell Type-Specific FGF13 Regulation of Neuronal Function
Serranilla Chloride Dysregulation and Impaired Gamma-Amino Butyric Acid Signaling in the Basal Ganglia in Huntington’s Disease
Ilaria et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
Gandhi Organisation of Glutamatergic Inputs to Central Amygdala
De Rocco Pharmacological modulation of neuronal activity for the treatment of Rett syndrome
CN1937914A (zh) 离子通道
KR20220025810A (ko) 스미스-마제니스 증후군을 치료하기 위한 방법 및 조성물
Senese Role of Regulator of G-Protein Signaling Proteins in Serotonin and Opioid Mediated Behaviors
WO2015047512A1 (en) Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
Heuermann The Role of HCN Channels and TRIP8b in Depression and Epilepsy
Lewis The role of TRIP8b in neuronal HCN channel trafficking and function
Al-Shammari Novel functions of schizophrenia-related dysbindin-1 in the subventricular zone

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190423

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250417

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414